Connors James J II Form 4 July 22, 2005

#### FORM 4

subject to

Section 16.

Form 4 or

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** Number:

3235-0287

0.5

Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires:

2005 Estimated average

**OMB APPROVAL** 

burden hours per response...

**SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

See Instruction

(Middle)

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Connors James J II

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

below)

Symbol

(Check all applicable)

**ENDO PHARMACEUTICALS** HOLDINGS INC [ENDP]

3. Date of Earliest Transaction

\_X\_\_ 10% Owner Director \_ Other (specify Officer (give title

C/O KELSO & COMPANY, 320

(Street)

(First)

PARK AVENUE

(Last)

4. If Amendment, Date Original

07/22/2005

Filed(Month/Day/Year)

(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

NEW YORK, NY 10022

(City)	(State) (2	Zip) Table	e I - Non-D	erivative	Securi	ties Acq	quired, Disposed	of, or Beneficial	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securi on(A) or D (D) (Instr. 3,	4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$.01 per share	07/22/2005		X	2,181	D	\$ 3	48,849,518	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	07/22/2005		X	1,406	D	\$ 2.42	48,848,112	I	By Endo Pharma LLC
Common Stock, par value \$.01	07/22/2005		X	5,846	D	\$3	48,842,266	I	By Endo Pharma LLC

per share								
Common Stock, par value \$.01 per share	07/22/2005	X	599	D	\$ 2.42	48,841,666	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	07/22/2005	X	778	D	\$ 3	48,840,888	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	07/22/2005	X	339	D	\$ 2.42	48,840,550	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	07/22/2005	X	2,314	D	\$ 2.42	48,838,236	I	By Endo Pharma LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number owf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ive Expiration Date (Month/Day/Year) of		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	\$ 3	07/22/2005		X		2,181	04/29/2005	08/26/2007	Common Stock	2,181
Call Option (obligation to sell)	\$ 2.42	07/22/2005		X		1,406	04/29/2005	08/26/2007	Common Stock	1,406
Call Option (obligation	\$ 3	07/22/2005		X		5,846	03/28/2005	08/26/2007	Common Stock	5,846

SEC 1474

(9-02)

to sell)								
Call Option (obligation to sell)	\$ 2.42	07/22/2005	X	599	03/28/2005	08/26/2007	Common Stock	599
Call Option (obligation to sell)	\$ 3	07/22/2005	X	778	03/28/2005	08/26/2007	Common Stock	778
Call Option (obligation to sell)	\$ 2.42	07/22/2005	X	339	03/28/2005	08/26/2007	Common Stock	339
Call Option (obligation	\$ 2.42	07/22/2005	X	2,314	11/29/2004	08/26/2007	Common Stock	2,314

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Connors James J II							
C/O KELSO & COMPANY		X					
320 PARK AVENUE		Λ					
NEW YORK, NY 10022							

# **Signatures**

to sell)

/s/ James J.
Connors, II

\*\*Signature of Reporting
Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3